无高风险HLA-DR3/DR4单倍型个体的1型糖尿病遗传发现与风险预测
研究在12,316例非DR3/DR4样本中鉴定出18个1型糖尿病风险变异,发现MHC及多个位点的效应依赖DR3/DR4状态存在异质性,非DR3/DR4者多基因负荷更大。新构建的非DR3/DR4遗传风险评分在区分非DR3/DR4 1型糖尿病与无糖尿病(AUC 0.867)及2型糖尿病(AUC 0.907)方面优于现有GRS2。
要点
- 非DR3/DR4样本中鉴定出18个1型糖尿病风险变异。
- MHC及多个位点风险变异对1型糖尿病的效应依赖DR3/DR4状态。
- 非DR3/DR4遗传风险评分区分1型糖尿病与无糖尿病的AUC为0.867。
核心结论
- 1型糖尿病遗传风险依赖高风险HLA-DR3/DR4单倍型存在异质性,有助于揭示疾病机制并在不同HLA背景下更准确预测1型糖尿病。
研究设计与样本
- 在12,316例非DR3/DR4样本中进行1型糖尿病关联分析和精细定位分析。
- 进行异质性检验以比较非DR3/DR4与DR3/DR4个体中1型糖尿病风险变异的差异。
- 评估非DR3/DR4与DR3/DR4队列之间基因调控元件和生物学通路富集的全基因组差异。
- 开发非DR3/DR4遗传风险评分(GRS)用于预测非DR3/DR4个体1型糖尿病,并与现有1型糖尿病GRS比较。
主要发现
- 非DR3/DR4样本中鉴定出18个1型糖尿病风险变异。
- MHC及全基因组多个其他位点的风险变异对1型糖尿病的效应依赖DR3/DR4状态存在异质性,非DR3/DR4 1型糖尿病有多基因负荷更大的证据。
- 非DR3/DR4中1型糖尿病相关变异较DR3/DR4更富集于抗原呈递、先天免疫和β细胞相关调控元件与通路,在T细胞中 depleted。
- 非DR3/DR4 GRS在区分非DR3/DR4 1型糖尿病与无糖尿病方面优于现有风险评分GRS2(AUC 0.867;P=7.48×10-32)。
- 非DR3/DR4 GRS在区分非DR3/DR4 1型糖尿病与2型糖尿病方面优于GRS2(AUC 0.907;P=4.94×10-44)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: More than 10% of patients with type 1 diabetes (T1D) do not have high-risk HLA-DR3 or -DR4 haplotypes with distinct clinical features, such as later onset and reduced insulin dependence. We aimed to identify genetic drivers of T1D in the absence of DR3/DR4 and improve prediction of T1D risk in these individuals. RESEARCH DESIGN AND METHODS: We performed T1D association and fine-mapping analyses in 12,316 non-DR3/DR4 samples. Next, we performed heterogeneity tests to examine differences in T1D risk variants in individuals without versus those with DR3/DR4 haplotypes. We further assessed genome-wide differences in gene regulatory element and biological pathway enrichments between the non-DR3/DR4 and DR3/DR4 cohorts. Finally, we developed a genetic risk score (GRS) to predict T1D in individuals without DR3/DR4 and compared with an existing T1D GRS. RESULTS: A total of 18 T1D risk variants in non-DR3/DR4 samples were identified. Risk variants at the MHC and multiple other loci genome wide had heterogeneity in effects on T1D dependent on DR3/DR4 status, and non-DR3/DR4 T1D had evidence for a greater polygenic burden. T1D-associated variants in non-DR3/DR4 were more enriched for regulatory elements and pathways involved in antigen presentation, innate immunity, and β-cells and depleted in T cells compared with DR3/DR4. A non-DR3/DR4 GRS outperformed an existing risk score GRS2 in discriminating non-DR3/DR4 T1D from no diabetes (area under the curve 0.867; P = 7.48 × 10-32) and type 2 diabetes (0.907; P = 4.94 × 10-44). CONCLUSIONS: In total, we identified heterogeneity in T1D genetic risk dependent on high-risk HLA-DR3/DR4 haplotype, which uncovers disease mechanisms and enables more accurate prediction of T1D across the HLA background.
引用
- McGrail C, Chiou J, Elgamal R, et al. Genetic Discovery and Risk Prediction for Type 1 Diabetes in Individuals Without High-Risk HLA-DR3/DR4 Haplotypes. Diabetes Care. 2025. PMID: 39626097. doi:10.2337/dc24-1251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。